Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BulgariaBack to Bulgaria

Clinical trials in Sofia – page 37

763 clinical trials in Sofia, Bulgaria across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sofia at a glance
763
clinical trials
  • Research sites17
Type of trial
Recruitment status
Quick filters

763 trials in Sofia

Open in trial search

Chronic obstructive pulmonary disease

Not recruiting

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Acute coronary syndrome

Not recruiting

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Hypertriglyceridaemia

Not recruiting

Study on the Effects of Pegozafermin and Simvastatin for Patients with Severe High Triglycerides

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bio89-100
  • Sponsor:89bio Inc.

Systemic lupus erythematosus

Not recruiting

Study on the Safety and Effectiveness of ESK-001 for Adults with Systemic Lupus Erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Esk-001
  • Sponsor:Alumis Inc.

Sjogren's syndrome

Not recruiting

Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Vib1116
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Obesity

Not recruiting

Study of KAI-9531 in Adults With Obesity or Overweight and Weight-Related Health Problems Without Diabetes

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:HRS 9531

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Sofia

What the registry says about research in the country

01 Respiratory Research

Clinical studies focusing on respiratory infections and conditions, including trials for RSV, human metapneumovirus, and influenza vaccines in older adults. Research also includes investigations into asthma treatments and chronic rhinosinusitis management.

  • Respiratory Syncytial Virus (RSV)
  • Influenza Prevention
  • Chronic Rhinosinusitis
  • Asthma Management
02 Dermatological Studies

Comprehensive research into various skin conditions, evaluating new treatments for chronic urticaria, hidradenitis suppurativa, and different forms of psoriasis. These trials aim to improve patient outcomes through innovative therapeutic approaches.

  • Chronic Spontaneous Urticaria
  • Hidradenitis Suppurativa
  • Genital Psoriasis
  • Plaque Psoriasis
03 Autoimmune Disorders

Groundbreaking studies examining treatments for various autoimmune conditions, including multiple sclerosis, Sjögren's disease, and systemic sclerosis. Research focuses on developing targeted therapies to manage these chronic conditions.

  • Multiple Sclerosis
  • Sjögren's Disease
  • Systemic Sclerosis
  • Psoriatic Arthritis
04 Metabolic and Cardiovascular Research

Studies investigating treatments for metabolic disorders and heart conditions, including research on hypertriglyceridemia, obesity management, and heart failure prevention. Focus on both therapeutic interventions and preventive measures.

  • Hypertriglyceridemia
  • Obesity Management
  • Heart Failure Prevention
  • Cardiovascular Health
05 Oncology Research

Advanced clinical trials focusing on breast cancer treatments and blood disorders, particularly investigating new therapeutic approaches for advanced/metastatic breast cancer and myelodysplastic syndrome.

  • Advanced Breast Cancer
  • Myelodysplastic Syndrome
  • Targeted Therapies
Back to BulgariaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.